Co-expression of Mesothelin and CA125/MUC16 is a Prognostic Factor for Breast Cancer, Especially in Luminal-type Breast Cancer Patients

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2021 Oct 30

PMID 34715925

Citations 5

Authors

Takahiro Einama

Yoji Yamagishi

Yasuhiro Takihata

Takafumi Suzuki

Tamio Yamasaki

Yuichi Hirose

Kazuki Kobayashi

Naoto Yonamine

Ibuki Fujinuma

Takazumi Tsunenari

Makiko Koga

Yusuke Ishibashi

Ken Nagata

Takehiro Shiraishi

Akiko Nakazawa

Toshimitsu Iwasaki

Eiji Shinto

Kimi Kato

Kimiya Sato

Hideki Ueno

Yoji Kishi

Hitoshi Tsuda

Affiliations

Soon will be listed here.

Abstract

The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox's multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.

Citing Articles

Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer.

Duan H, Liu X, Zhang Y, Liu Y, Ji Y, Zhang Y J Ovarian Res. 2024; 17(1):210.

PMID: 39462415 PMC: 11514894. DOI: 10.1186/s13048-024-01535-9.

Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients.

Geng J, Jinli S, Guo W, Li H, Dan Y, Gao Y J Med Biochem. 2024; 43(2):234-242.

PMID: 38699697 PMC: 11062330. DOI: 10.5937/jomb0-45192.

S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1.

Zhang X, Niu M, Li T, Wu Y, Gao J, Yi M Biomark Res. 2023; 11(1):106.

PMID: 38093319 PMC: 10720252. DOI: 10.1186/s40364-023-00548-8.

The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury.

Nishio T, Koyama Y, Fuji H, Ishizuka K, Iwaisako K, Taura K Biology (Basel). 2022; 11(11).

PMID: 36358290 PMC: 9687690. DOI: 10.3390/biology11111589.

Bioinformatics Analysis Based on TCGA: MUC16 Mutation Correlates with Clinical Outcome in Gastric Cancer.

Huang L, Zheng S, Fu J, Zhang M, Ge X, Mu N Dis Markers. 2022; 2022:6734105.

PMID: 36051359 PMC: 9427262. DOI: 10.1155/2022/6734105.

References

Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M . Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. PMC: 1635730. DOI: 10.1186/1476-4598-5-50. View

Chang K, Pai L, Pass H, Pogrebniak H, Tsao M, Pastan I . Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992; 16(3):259-68. DOI: 10.1097/00000478-199203000-00006. View

Kaneko O, Gong L, Zhang J, Hansen J, Hassan R, Lee B . A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2008; 284(6):3739-49. PMC: 2635045. DOI: 10.1074/jbc.M806776200. View

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M . Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2003; 279(10):9190-8. DOI: 10.1074/jbc.M312372200. View

Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N . Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012; 107(1):137-42. PMC: 3389425. DOI: 10.1038/bjc.2012.235. View

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K . Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011; 40(8):1276-82. DOI: 10.1097/MPA.0b013e318221bed8. View

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz R . Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7(12):3862-8. View

Suzuki T, Yamagishi Y, Einama T, Koiwai T, Yamasaki T, Fukumura-Koga M . Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer. Oncol Lett. 2020; 20(5):193. PMC: 7479516. DOI: 10.3892/ol.2020.12055. View

Ordonez N . Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27(11):1418-28. DOI: 10.1097/00000478-200311000-00003. View

10.

Ho M, Hassan R, Zhang J, Wang Q, Onda M, Bera T . Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005; 11(10):3814-20. DOI: 10.1158/1078-0432.CCR-04-2304. View

11.

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View